Pfizer’s Bold Move in Weight Loss Drugs

Pfizer is making a bold move in the weight-loss drug race with new data on berobenatide, a once-a-month shot that slashed body weight by nearly 16% in trials — aiming to rival Eli Lilly and Novo Nordisk. Beyond just shedding pounds, the drug could treat diabetes and knee pain, tapping into a booming obesity market. With blockbuster experience from Viagra and Lipitor, Pfizer is betting big on scale, global trials, and patient access to capture a major slice of this long-term revenue stream — and they’re not stopping there, exploring pills and quarterly treatments to stay ahead. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0bdbba7ef2a4b585